Sonoma Pharmaceuticals
SNOASonoma Pharmaceuticals leverages its proprietary Microcyn® Technology, the world's first patented and shelf-stable hypochlorous acid formulation, to address a broad range of infection control and skin health needs. With a global presence in over 50 countries, a portfolio backed by numerous patents and regulatory approvals, and a product line spanning wound care, dermatology, and consumer health, the company is positioned as a leader in HOCl-based solutions. Its strategic direction includes expanding direct offerings in dermatology and eye care, while pursuing wholesale, partnership, and distributor opportunities to grow its market reach.
SNOA · Stock Price
Historical price data
AI Company Overview
Sonoma Pharmaceuticals leverages its proprietary Microcyn® Technology, the world's first patented and shelf-stable hypochlorous acid formulation, to address a broad range of infection control and skin health needs. With a global presence in over 50 countries, a portfolio backed by numerous patents and regulatory approvals, and a product line spanning wound care, dermatology, and consumer health, the company is positioned as a leader in HOCl-based solutions. Its strategic direction includes expanding direct offerings in dermatology and eye care, while pursuing wholesale, partnership, and distributor opportunities to grow its market reach.
Technology Platform
Microcyn® Technology is a patented, shelf-stable formulation platform for hypochlorous acid (HOCl), mimicking the body's natural immune response, with superior stability and a broad-spectrum antimicrobial and anti-inflammatory profile.
Pipeline
3| Drug | Indication | Stage | Watch |
|---|---|---|---|
| SBT115301 + Placebo | Safety | Phase 1 | |
| SBT777101 | Rheumatoid Arthritis | Phase 1 | |
| SBT777101 | Hidradenitis Suppurativa | Phase 1 |
Funding History
3Opportunities
Risk Factors
Competitive Landscape
Sonoma competes against other hypochlorous acid producers and broader antiseptic solutions (povidone-iodine, silver). Its main differentiation lies in its patented, shelf-stable Microcyn® Technology, a first-mover advantage in HOCl, an extensive safety profile, and a diversified commercial portfolio spanning Rx and OTC markets.